Every year, millions of people worldwide receive blood transfusions or blood products. The blood screening market, valued at USD 1.8 billion in 2020 and expected to reach USD 4.6 billion by 2028, highlights the critical nature of ensuring blood safety. Sansure, an innovator in the field of molecular diagnostics, focuses on advanced testing solutions to protect patients from transfusion-related infections.
The Challenge of Transfusion-Transmitted Infections
Despite rigorous testing protocols, transfusion-transmitted infections remain a concern, particularly with the prevalence of HIV, HBV, and HCV. The traditional immunoassay testing method has its limitations, particularly during the window period (WP), where infections may go undetected. This is a significant drawback, emphasizing the need for enhanced screening methods such as NAT testing of blood.
Advantages of NAT Testing
What is NAT testing of blood? It offers a solution to the limitations faced by traditional testing methods. It can detect viral RNA or DNA in donor samples much earlier than serological tests, effectively shortening the window period to 10.34 days for HBV and 2.93 days for HIV. This capability not only improves patient safety but also strengthens the overall integrity of the blood supply.
Sansure’s Innovative Solutions
Sansure is committed to advancing blood safety through its state-of-the-art NAT testing technologies. By prioritizing rapid and accurate detection, Sansure helps healthcare providers ensure that blood products are free from harmful infections, thereby safeguarding millions of patients.
Conclusion
NAT testing of blood plays a pivotal role in enhancing the safety of transfusions. As the blood screening market evolves, embracing innovative technologies like those offered by Sansure is essential for protecting public health and ensuring safer blood products.
